Company Overview

PTC Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of medicines for rare disorders and conditions with high unmet medical need. The company operates within the biotechnology and pharmaceutical industries, with a core emphasis on genetic, neuromuscular, metabolic, and neurodegenerative diseases. Its business model combines internal research and development with strategic collaborations to advance therapies from discovery through commercialization.

PTC Therapeutics’ primary revenue drivers include sales of approved therapies, milestone payments, and collaboration-related revenues. Key marketed products include Translarna, Upstaza, and Evrysdi (the latter through a global collaboration). The company is recognized for its expertise in RNA biology and small-molecule drug discovery, particularly therapies designed to target the underlying genetic causes of disease. Founded in 1998, PTC Therapeutics evolved from an early-stage research company into a commercial-stage organization following regulatory approvals in Europe and select international markets, while continuing to expand its clinical pipeline.

Business Operations

PTC Therapeutics operates through a single integrated business model encompassing research, clinical development, regulatory activities, manufacturing oversight, and commercialization. Its operations are organized around therapeutic focus areas rather than formally reported operating segments, with primary concentration in neuromuscular diseases, metabolic disorders, and neurogenetic conditions. Revenue is generated from product sales outside the United States, collaboration agreements, and license and royalty income.

The company maintains global research and development capabilities, leveraging proprietary drug discovery platforms and clinical development expertise. Manufacturing is primarily outsourced to third-party contract manufacturers, while commercialization is conducted directly in certain regions and through partners elsewhere. Key collaborations include long-standing partnerships with major pharmaceutical companies to co-develop and commercialize specific assets, most notably the global collaboration for Evrysdi.

Strategic Position & Investments

PTC Therapeutics’ strategy centers on expanding its rare disease portfolio through internal innovation, lifecycle management of approved products, and targeted acquisitions or licensing transactions. Growth initiatives include advancing late-stage clinical programs, pursuing additional regulatory approvals across geographies, and broadening indications for existing therapies. The company continues to invest heavily in its pipeline, with multiple candidates in clinical development addressing both ultra-rare and broader rare disease populations.

Notable strategic investments include the development and commercialization of Upstaza, the first approved gene therapy administered directly to the brain for a rare pediatric neurological disorder. PTC Therapeutics also maintains equity interests and economic rights in partnered programs, allowing it to participate in long-term value creation without bearing full development or commercialization risk. Emerging areas of focus include gene therapies, RNA-based medicines, and small-molecule approaches targeting disease-modifying pathways.

Geographic Footprint

PTC Therapeutics is headquartered in the United States, with its principal executive offices in New Jersey. The company has a significant international presence, particularly in Europe, where several of its products have received regulatory approval and generate a substantial portion of commercial revenue. Additional operations and commercial activities extend across North America, Latin America, the Middle East, and parts of Asia-Pacific through a combination of direct operations and distribution partners.

The company’s global footprint supports clinical trials in multiple regions and enables access to diverse patient populations for rare disease studies. International expansion remains a strategic priority, especially in markets with established rare disease regulatory frameworks and reimbursement pathways.

Leadership & Governance

PTC Therapeutics is led by an experienced management team with deep expertise in biotechnology, rare disease drug development, and global commercialization. The leadership emphasizes a patient-centric philosophy, scientific rigor, and long-term value creation through innovation and disciplined capital allocation.

Key executives include:

• Matthew B. Klein – Chief Executive Officer
• Stuart W. Peltz – Founder and Chief Scientific Officer
• James M. Fallon – Chief Financial Officer
• Jerome T. Boyce – President, International
• Kathryn A. Boor – Chief Operating Officer

The company is governed by a board of directors with experience spanning pharmaceuticals, finance, and corporate governance, providing oversight of strategy, risk management, and regulatory compliance.